eGFR (2021 CKD-EPI)
Classifies Chronic Kidney Disease (CKD) stages G1 through G5 and adjusts drug dosages.
eGFR (2021 CKD-EPI) Parameters
About the eGFR (2021 CKD-EPI)
Race-free equation recommended by NKF and ASN to estimate renal glomerular filtration rate from serum creatinine.
Scoring Methodology & Interpretation
The eGFR (2021 CKD-EPI) uses a validated formula algorithm with predefined clinical cutoffs established in peer-reviewed derivation and validation cohorts:
| Score Range | Severity Classification | Clinical Interpretation |
|---|---|---|
| 90 – 160 | Stage G1: Normal or High | Normal kidney filtration function. |
| 60 – 89 | Stage G2: Mildly Decreased | Common in healthy older adults. |
| 45 – 59 | Stage G3a: Mildly to Moderately Decreased | Diagnostic of CKD if sustained for greater than 3 months. |
| 30 – 44 | Stage G3b: Moderately to Severely Decreased | Significant chronic renal impairment. |
| 15 – 29 | Stage G4: Severely Decreased | Advanced chronic kidney disease. |
| 0 – 14 | Stage G5: Kidney Failure | End-stage kidney disease / kidney failure. |
Clinical Pearls & Considerations
- The 2021 CKD-EPI formula eliminates the race coefficient to provide equitable, physiology-based renal assessment.
Developed by Inker LA et al. (NEJM 2021) under ASN & NKF joint task force guidance.
This instrument is designed for educational, informational, and clinical reference purposes. Screening scores do not constitute a definitive medical diagnosis. Individual clinical management must integrate full diagnostic history, physical examination, and laboratory data by a licensed healthcare professional.
- Inaccurate in acute kidney injury, extreme body size/amputees, or individuals following strict vegan diets or taking creatine supplements.
- Cystatin C-based equations should be considered when creatinine-based eGFR is suspected to be discordant with true GFR.
Evidence & Primary Literature Citations
- Key Validation StudyNew Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.Inker LA, Eneanya ND, Coresh J, et al. N Engl J Med. 2021;385:1737-1749.
Related Validated Instruments
Clinical calculator for Body Mass Index (WHO/CDC) and Mosteller Body Surface Area.
Validated clinical risk score predicting annual thromboembolic stroke risk in non-valvular atrial fibrillation.